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Abstract: In the present study, we investigated the relationships between several molecular properties and bioavailability 
data for seven of the most commonly prescribed angiotensin II receptor antagonists (also known as angiotensin II recep-
tor blockers (ARBs) or sartans), candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan and valsartan. The 
molecular descriptors of ARBs are:, aqueous solubility (logS values), polar surface area (PSA), molecular weight (Mw), 
volume value (Vol), lipophilicity (logP values) and the acidity descriptor (pKa1). The respective descriptors were calculated 
using four different software packages. The relevant bioavailability data were obtained from literature. Among calculated 
molecular descriptors, simple linear regression analysis showed the best correlation between bioavailability data and the 
lipophilicity descriptor, logP (R2=0.568). Multiple linear regression established good correlations between bioavailability 
and the lipophilicity descriptor, logP, using the molecular weight, Mw, or the acidity descriptor, pKa1, as an additional, 
independent variable (with R2=0.661 and 0.682, respectively). Finally, excluding candesartan from the calculations resulted 
in a very good correlation (R2=0.852) between the remaining ARB bioavailability and molecular descriptors MlogP and 
Mw as independent variables, determined by multiple linear regression.
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INTRODUCTION
The ARB were introduced into clinical practice three 
decades ago and today are commonly prescribed for 
the treatment of hypertension, congestive heart failure 
and diabetic nephropathy [1]. ARBs are acidic drugs 
that are mostly ionized at physiological conditions [1]. 
In contrast to other ARBs, candesartan cilexetil and 
olmesartan medoxomil are rapidly and completely 
hydrolyzed in the intestinal wall into their active me-
tabolites, candesartan and olmesartan, respectively. 
Approximately 14% of ingested losartan is oxidized to 
a more potent metabolite, while other ARBs are not 
converted to active metabolites. Although all ARBs 
have the same indications for usage, they demonstrate 
certain differences in pharmacological, pharmacoki-
netic and pharmacodynamic properties, which may 
affect their clinical efficacy. They have relatively high 
plasma protein binding (PPB) values (95-100%). With 
the exception of irbesartan with an oral bioavailability 
(BA) of 60-80% and telmisartan with BA of 42-58%, 
all other ARBs have lower (15-33%), but adequate val-
ues of oral bioavailability. Most of these compounds 
are excreted unchanged. They have a dual route of 
elimination, renal and fecal, which may be of impor-
tance for patients with renal failure [2-4]. 
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Molecular properties such as lipophilicity, acidity, 
molecular weight, molecular volume, polar surface 
area and water solubility, play an important role in 
drug absorption, penetration into tissues, degree of 
distribution, degree of PPB, bioavailability and route 
of elimination [5-9]. Several authors have investigat-
ed the pharmacological properties of ARBs [10-12]. 
The drugs’ lipophilicity, solubility and absorption 
were evaluated with computer software based on the 
drugs’ molecular structure [7-9]. Also, various authors 
suggested several assays that could be employed in in-
vestigating the elimination of different drugs [13-16].
In our recently published paper we assessed the 
correlation of the degree of PPB and the elimination of 
a selected ARBs with their molecular properties, mo-
lecular weight and volume using multiple regression 
(MLR) analysis [17,18]. In our previous studies, the cor-
relation between ACE inhibitor lipophilicity and PPB 
data [19,20] or absorption [21] were studied and suitable 
models were presented. Following on from this work, 
the aim of our present study was to investigate the rela-
tionship between the different molecular properties of 
seven ARBs, candesartan, eprosartan, irbesartan, losar-
tan, olmesartan, telmisartan, valsartan, and their BA. 
MATERIALS AND METHODS
Software
The seven most frequently prescribed ARB were 
investigated: candesartan, eprosartan, irbesartan, 
losartan, olmesartan, telmisartan and valsartan. The 
software package Molinspiration Depiction Software 
(Molinspiration Cheminfirmatics) was used for the 
calculation of the “electronic” descriptors, polar sur-
face area (PSA), constitutional parameter, molecular 
weight (Mw), and the geometric descriptor, volume 
value (Vol). The ARB lipophilicity descriptors, dif-
ferent logP values (AlogPs, AClogP, AB/logP, MilogP, 
AlogP, MlogP, KOWWINlogP, XLOGP2, XLOGP3), 
as well as their aqueous solubility data (logS) were cal-
culated using the software package Virtual Computa-
tional Chemistry Laboratory [http://www.vcclab.org]. 
Chemdraw ultra 12.0 was used for the calculation of 
another lipophilicity parameter, ClogP, while the soft-
ware package DrugBank [http: //www.drugbank.ca] 
was used for the calculation of the acidity descriptor 
pKa of the selected ARB. Microsoft Excel 2003 and 
Origin 7.0 PRO (Origin Lab Corporation, USA) were 
used to perform statistical analysis of regression. The 
selected molecular descriptors are presented in Table 
1; the provided oral bioavailability data were obtained 
from the relevant literature [2].
RESULTS 
According to data from the relevant literature, the de-
grees of ARB BA vary from 15% to about 70% (Table 
2) and [3]. Eprosartan has the lowest oral BA (15%), 
while the highest were recorded for telmisartan and 
irbesartan (about 50% and 70%, respectively). The 
ARB molecular descriptors PSA, Mw, Vol, logS, logP 
and pKa values, were calculated using four different 
software packages. 
The correlations between ARB oral BA data ob-
tained from the literature and all calculated descrip-
Table 1. Data of ARB oral bioavailability collected from relevant 
literature and calculated molecular descriptors. 
ARB BA%* MlogP pKa1 Mw PSA Vol logs
1. Candesartan 15 4.55 2.97 440 119 382 -5.30
2. Eprosartan 15 3.42 3.63 424 92 381 -3.60
3. Irbesartan 70 5.11 7.40 428 87 400 -5.28
4. Losartan 33 4.55 7.40 422 92 374 -4.63
5. Olmesartan 26 4.01 0.91 446 130 403 -4.68
6. Telmisartan 50 5.70 3.65 514 73 475 -5.72
7. Valsartan 25 4.15 4.37 435 112 408 -4.86
*BA values were obtained from the literature [3]
Table 2. Data of ARB oral bioavailability collected from relevant 
literature (*) and predicted from (A) MlogP and Vol; (B) MlogP 
and PSA; (C) MlogP and Mw; (D) MlogP and pKa1 values.
ARB BA %* BA % (A) BA % (B) BA % (C) BA % (D)
1. Candesartan 15 36 29 36 30
2. Eprosartan 15 11 18 9 13
3. Irbesartan 70 47 47 55 53
4. Losartan 33 37 36 40 44
5. Olmesartan 26 23 18 19 15
6. Telmisartan 50 55 60 48 52
7. Valsartan 25 25 24 26 28
*BA values were obtained from the literature [3]
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tors were investigated by simple linear regression. The 
oral BA data and the ARB molecular descriptors, Vol, 
Mw, logS and pKa1, displayed low correlations (R2<0.3) 
and only PSA had a slightly stronger correlation 
(R2=0.361) with ARB oral BA data. The relationship 
between all ten lipophilicity descriptors, logP values 
and oral BA data were examined, and mostly pro-
vided low correlations (R2<0.3). The strongest, but not 
sufficiently high correlation was established between 
MlogP and oral BE data (R2=0.567). 
In the next stage, the relationship between BA data 
and two different ARB molecular descriptors as inde-
pendent variables were investigated with MLR. MlogP 
was chosen as the first independent variable since it 
showed the best correlation with ARB oral BA data in 
simple linear regression. The solubility data could not be 
used as the second independent variable since logS pro-
vided good correlation with MlogP values (R2=0.805). 
Therefore, PSA, Mw, Vol and pKa1 were chosen as pos-
sible, secondary independent variables, besides MlogP. 
















(R2=0.682; n=7 S.D.=13.85; F=4.29). 
The best correlation was established between ARB 
BA data obtained from the literature and the MlogP 
lipophilicity descriptor, using Mw or the acidity de-
scriptor pKa1 as additional, independent variables with 
R2=0.661 and 0.682, respectively. The obtained results 
are presented in Table 2. It can be noticed that among 
the investigated ARB candesartan’s predicted BA val-
ues were twice as high as those found in the avail-
able BA data for all obtained calculations. Therefore, 
it was decided to repeat calculations after excluding 
candesartan, and a significantly higher correlation was 
found in the first stage in simple linear regression be-
tween ARB BA data and MlogP values with R2=0.702. 
Subsequently, MLR analysis also provided a much bet-
ter relationship between available BA data for ARB in 
the literature and all the calculated molecular descrip-
tors, PSA, Mw, Vol and pKa1 (R2>0.70). The best MLR 
analysis was established with the application of MlogP 




(with R2=0.852; n=6; S.D.=9.98; F=8.63). 
The established correlation is presented in Fig.1. 
Fig. 1. The relationship between ARB oral bioavailability data 
collected from the literature [3] (Series 1) and predicted in MLR, 
using MlogP and Mw, after candesartan exclusion (Series 2). The 
numbers denote ARB as presented in Table 1.
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DISCUSSION
Oral BA is one of the most important pharmacologic 
properties in drug design and development. It is a 
subcategory of absorption and represents the frac-
tion of administered drug dose that reaches systemic 
circulation. High oral BA reduces the amount of an 
administered drug needed to achieve the desired 
pharmacological effect, thereby reducing the risk of 
side effects and toxicity, while poor oral BA can result 
in low efficacy and lead to unpredictable response to 
a drug. BA for intravenously administered drugs is 
100%. However, for orally administered drugs, BA 
usually decreases due to incomplete absorption and 
first-pass metabolism as well a high degree of plasma 
protein binding. Various physiological factors may 
reduce the bioavailability of drugs prior to their en-
try into the systemic circulation. Furthermore, drug 
administration with or without food also affects ab-
sorption. Concurrent intake of other drugs may alter 
absorption and first-pass metabolism, while intestinal 
motility alters the dissolution and may affect the de-
gree of chemical degradation of the drug by intesti-
nal microflora. Diseases affecting liver metabolism 
or gastrointestinal function will also have an effect 
on BA. A drug’s physical properties (hydrophobicity, 
acidity, solubility, molecular mass, volume and polar 
surface area) or its formulation as well as the age and 
gender of the patients and the dosing scheme also 
exert important influences on its BA. 
Previous studies evaluated the acidity, lipophilic-
ity, solubility and absorption of different drugs based 
on their molecular structure with the application of 
computer programs [7-9]; they also evaluated the in-
fluence of molecular properties on drug BA [22,23], 
but ARB were not included in these studies. According 
to the available literature, the ARB pharmacokinet-
ics and pharmacodynamics, including their effects 
and duration of action, were investigated by several 
authors [24-29]. However, most of these methods had 
certain limitations and a new approach for a fast, easy 
and reliable evaluation of ARB oral BA was necessary. 
The central aim of the study was to establish a 
high throughput approach for evaluating the oral BA 
data of selected ARB using simple or multiple linear 
regression analyses. In the first stage of the study, the 
relationship between all calculated logP values (ClogP, 
AlogPs, AClogP, AB/logP, milogP, AlogP, MlogP, 
KOWWINlogP, XLOGP2, XLOGP3) and ARB oral 
BA data were investigated. Of all logP values, only 
MlogP provided relatively good correlation (R2=0.567) 
with ARB oral BA. The methods used for lipophilic-
ity descriptor calculation provided ten different logP 
values. They can be divided into substructure-based 
and property-based methods, and the substructure-
based methods can be additionally subclassified into 
fragmental and atom-based [30]. The lipophilicity 
descriptor MlogP was calculated with the property-
based method based on topological descriptors [30]. 
Secondly, the relationship between ARB and BA 
data and calculated molecular descriptors was in-
vestigated using MLR analysis with the application 
of two independent variables, MlogP and one of the 
following: PSA, Mw, Vol or pKa. Although the best 
correlation was established between ARB BA data and 
the MlogP lipophilicity descriptor, using the molecu-
lar weight (R2=0.661) or acidity (R2=0.682) as inde-
pendent variables it was observed that the calculated 
BA values for candesartan differed notably from its 
literature available BA values (Table 2). Candesar-
tan is actually an active metabolite and its prodrug 
form is candesartan cilexetil. Candesartan cilexetil 
is absorbed after oral administration and hydrolyzed 
during absorption to form candesartan. An absolute 
bioavailability for candesartan is about 15% following 
its oral administration. Peak plasma concentration oc-
curs after 3 to 4 h. Candesartan has very high degree 
of plasma protein binding (PPB), higher than 99%. 
The high values of candesartan’s PPB, together with 
incomplete absorption and first-pass metabolism may 
be some of the reasons for its low BA values. 
Following this observation, candesartan was ex-
cluded from further investigation resulting in much 
higher correlation (R2=0.702) between ARB BA data 
and MlogP values calculated using simple linear re-
gression. MLR analysis of ARB BA data and the li-
pophilicity descriptor MlogP, with the application of 
different molecular descriptors established satisfactory 
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correlations (R2>0.70), the best (R2>0.852) being Mw 
as an independent variable, confirming the important 
influence of ARB molecular properties on their oral 
BA. The results obtained can be considered as good 
considering the limited number of compounds and 
since values of R2 higher than 0.81 are proposed as 
very high correlation by Asuero et al. [31]. 
CONCLUSION
The results of the present paper have confirmed that 
the molecular properties, especially lipophilicity, acid-
ity and molecular weight of angiotensin II receptor 
blockers, are of considerable importance and that their 
calculation can be considered as a high-throughput 
screening for evaluation of the oral bioavailability of 
the selected compounds. For the selected group of an-
giotensin II receptor blockers, simple linear regression 
analysis provided a correlation (R2=0.568) between the 
calculated lipophilicity descriptor and bioavailability 
data. However, in multiple linear regression, better 
correlations were established between the bioavail-
ability and lipophilicity descriptor, using the molecular 
weight or the acidity descriptor as additional, indepen-
dent variables (with R2=0.661 and 0.682, respectively). 
Candesartan exclusion from multiple linear regression 
analysis resulted in very good correlation (R2=0.852) 
between the remaining angiotensin II receptor block-
ers’ bioavailability, lipophilicity and molecular weight 
descriptors as independent variables. Since bioavailabil-
ity affects drug action and activity and is considerably 
influenced by molecular properties, the examination of 
its relationship with computed molecular descriptors 
can be of great importance, especially in the develop-
ment of newly synthesized drugs.
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